Literature DB >> 10235564

Dorzolamide effect on ocular blood flow.

A Martinez1, F Gonzalez, C Capeans, R Perez, M Sanchez-Salorio.   

Abstract

PURPOSE: To evaluate the effect of dorzolamide on ocular blood flow in normal and glaucomatous eyes.
METHODS: Twenty-six eyes with documented open-angle glaucoma of 26 patients and 13 normal control eyes of 8 age-matched subjects were included in this study. All eyes underwent color Doppler imaging for measuring peak-systolic velocity, end-diastolic velocity, and resistance index in the ophthalmic and central retinal arteries and the maximal and minimal velocities in the central retinal vein. Eyes were grouped in control and initial and advanced glaucoma categories. Measurements were made in all groups before and after application of topical dorzolamide. Intragroup comparisons between baseline and dorzolamide conditions were made using paired Student's t-test. Intergroup comparisons under baseline conditions between normal and glaucomatous eyes were made by using the one-way ANOVA test. Statistical significance was set at P < 0.05.
RESULTS: The peak-systolic velocity of the central retinal artery in glaucomatous eyes and the end-diastolic velocity of the ophthalmic and central retinal arteries in all groups were significantly higher after application of dorzolamide. The minimal velocity of the central retinal vein showed significantly higher values after dorzolamide, whereas the maximal velocity remained unchanged. The peak-systolic velocity of the ophthalmic artery in all groups and the peak-systolic velocity of the central retinal artery in normal eyes also remained unchanged. The resistance index was significantly lower in the ophthalmic and central retinal arteries in all groups after dorzolamide. The intraocular pressure was significantly reduced in all groups after dorzolamide. Under baseline conditions normal control eyes and glaucomatous eyes showed differences in various measurements. Peak-systolic velocity was significantly lower in glaucomatous eyes than in normal control eyes with the exception of the ophthalmic artery in the initial glaucoma group. End-diastolic velocity was lower in glaucomatous eyes than in control eyes in both arteries. Maximal and minimal velocities of the central retinal vein were lower in glaucomatous eyes than in normal control eyes. Resistance index was higher in glaucomatous eyes than in normal control eyes in the ophthalmic artery but not in the central retinal artery.
CONCLUSIONS: Most hemodynamic parameters of intraocular and periocular vessels improve after application of topical dorzolamide in both normal control and glaucomatous eyes. Dorzolamide should be regarded as a useful drug for treatment of glaucoma not only because it reduces intraocular pressure but also because it improves the ocular blood supply.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235564

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  21 in total

Review 1.  Evolving paradigms in the medical treatment of glaucoma.

Authors:  John S Cohen; Anup K Khatana; Linda J Greff
Journal:  Int Ophthalmol       Date:  2006-03-07       Impact factor: 2.031

2.  Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.

Authors:  Rajendra S Kadam; Gajanan Jadhav; Miller Ogidigben; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2011-06-14       Impact factor: 3.922

3.  Retrobulbar hemodynamic parameters in open-angle and angle-closure glaucoma patients.

Authors:  I Marjanovic; N Milic; A Martinez; J Benitez-del-Castillo
Journal:  Eye (Lond)       Date:  2012-01-13       Impact factor: 3.775

Review 4.  Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma.

Authors:  D Ormrod; K McClellan
Journal:  Drugs Aging       Date:  2000-12       Impact factor: 3.923

5.  Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension.

Authors:  G Fuchsjäger-Mayrl; B Wally; G Rainer; W Buehl; T Aggermann; J Kolodjaschna; G Weigert; E Polska; H-G Eichler; C Vass; L Schmetterer
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

6.  Factors associated with changes in retinal microcirculation after antihypertensive treatment.

Authors:  P R Antonio; P S Marta; D D J Luís; D P J Antonio; S T Manuel; M S Rafael; G V Sonia; G P Manuel; M-N Isabel; E N J Carlos; C T Gabriel; G U I Francisco
Journal:  J Hum Hypertens       Date:  2013-11-21       Impact factor: 3.012

7.  Carbonic anhydrase inhibition increases retinal oxygen tension and dilates retinal vessels.

Authors:  Daniella Bach Pedersen; Peter Koch Jensen; Morten la Cour; Jens Folke Kiilgaard; Thor Eysteinsson; Kurt Bang; Anne Kathrine Wiencke; Einar Stefánsson
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-11-30       Impact factor: 3.117

8.  Effects of dorzolamide on choroidal blood flow, ciliary blood flow, and aqueous production in rabbits.

Authors:  Herbert A Reitsamer; Barbara Bogner; Birgit Tockner; Jeffrey W Kiel
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-31       Impact factor: 4.799

9.  Effects of brinzolamide on ocular haemodynamics in healthy volunteers.

Authors:  M Kaup; N Plange; M Niegel; A Remky; O Arend
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

10.  Retrobulbar hemodynamic parameters in pseudoexfoliation syndrome and pseudoexfoliative glaucoma.

Authors:  Antonio Martinez; Manuel Sanchez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-20       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.